Literature DB >> 16883006

Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis.

Rachida Lebtahi1, Severine Moreau, Sylvain Marchand-Adam, Marie-Pierre Debray, Michel Brauner, Paul Soler, Joëlle Marchal, Olivier Raguin, Anne Gruaz-Guyon, Jean-Claude Reubi, Dominique Le Guludec, Bruno Crestani.   

Abstract

UNLABELLED: Idiopathic pulmonary fibrosis (IPF) is characterized by an uncontrolled accumulation and activation of lung fibroblasts. A modulation of fibroblast activation has been observed in various systems with octreotide, a synthetic somatostatin analog with strong affinity for the somatostatin receptor subtype 2 (sst2). One aim of our study was to evaluate the expression of somatostatin receptors in the lungs of patients with IPF. A second aim was to evaluate the relationship between 111In-octreotide uptake and the effect of pulmonary fibrosis as assessed by lung function tests and parameters and by radiologic findings.
METHODS: We investigated 11 patients with IPF, 6 patients with pulmonary fibrosis associated with systemic sclerosis (SSc), and 19 patients with disease not of the lung (control patients). The expression of somatostatin receptors was evaluated in vivo using 111In-octreotide scintigraphy. We evaluated the relationship between 111In-octreotide uptake and the activity of pulmonary fibrosis as assessed by lung function tests, bronchoalveolar lavage (BAL) cellularity, and high-resolution CT (HRCT) of the chest. Planar images and thoracic SPECT (24 h) were performed after injection of 222 MBq of 111In-octreotide. Lung uptake was quantified using the lung-to-background ratio (L/B). In addition, the expression of sst2 was evaluated in vitro, in frozen lung-tissue samples using autoradiography, and in human cultures of lung fibroblasts using a ligand-binding assay.
RESULTS: Compared with lung uptake in control patients (median L/B, 1.25; range, 1.14-1.49), lung uptake was increased in all 11 IPF patients (median L/B, 2.63; range, 1.59-3.13; P < 0.001) and in 4 of 6 SSc patients (median L/B, 1.68; range, 1.42-2.16). The L/B was lower in SSc patients than in IPF patients (P = 0.011). Increased uptake correlated with the alteration of lung function (carbon monoxide diffusing capacity [rho = -0.655; P = 0.038], diffusing capacity for carbon monoxide and alveolar volume ratio [rho = -0.627; P = 0.047], vital capacity [rho = -0.609; P = 0.054], and total lung capacity [rho = -0.598; P = 0.058]) and with the intensity of alveolitis (total BAL cellularity [rho = 0.756; P = 0.045], neutrophil counts [rho = 0.738; P = 0.05]), and HRCT fibrosis score (rho = 0.673; P = 0.007). Autoradiography suggested that vascular structures were a prominent binding site. Lung fibroblasts expressed somatostatin receptors in vitro as measured by binding assay.
CONCLUSION: Our preliminary results identified an increased expression of sst2 in (mainly idiopathic) pulmonary fibrosis. Lung uptake correlates with the alteration of lung function and with the intensity of alveolitis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16883006

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  22 in total

Review 1.  Coordinating radiometals of copper, gallium, indium, yttrium, and zirconium for PET and SPECT imaging of disease.

Authors:  Thaddeus J Wadas; Edward H Wong; Gary R Weisman; Carolyn J Anderson
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

Review 2.  Investigational approaches to therapies for idiopathic pulmonary fibrosis.

Authors:  Richard H Gomer; Mark L Lupher
Journal:  Expert Opin Investig Drugs       Date:  2010-06       Impact factor: 6.206

Review 3.  Somatostatin receptor scintigraphy in thoracic diseases.

Authors:  P Ameri; F Gatto; M Arvigo; G Villa; E Resmini; F Minuto; G Murialdo; D Ferone
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

4.  Imaging of molecular signatures of specific structures, functions,and pathological alterations in the lung tissue.Chair's Summary.

Authors:  Vladimir R Muzykantov
Journal:  Proc Am Thorac Soc       Date:  2009-08-15

Review 5.  Somatostatin receptor expression in non-classical locations - clinical relevance?

Authors:  Eldrin Bhanat; Christian A Koch; Rinkuben Parmar; Vishnu Garla; Vani Vijayakumar
Journal:  Rev Endocr Metab Disord       Date:  2018-06       Impact factor: 6.514

Review 6.  Imaging Pulmonary Inflammation.

Authors:  Philip M Scherer; Delphine L Chen
Journal:  J Nucl Med       Date:  2016-09-01       Impact factor: 10.057

7.  Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models.

Authors:  Pauline Désogère; Luis F Tapias; Lida P Hariri; Nicholas J Rotile; Tyson A Rietz; Clemens K Probst; Francesco Blasi; Helen Day; Mari Mino-Kenudson; Paul Weinreb; Shelia M Violette; Bryan C Fuchs; Andrew M Tager; Michael Lanuti; Peter Caravan
Journal:  Sci Transl Med       Date:  2017-04-05       Impact factor: 17.956

Review 8.  Molecular imaging of fibrosis: recent advances and future directions.

Authors:  Sydney B Montesi; Pauline Désogère; Bryan C Fuchs; Peter Caravan
Journal:  J Clin Invest       Date:  2019-01-02       Impact factor: 14.808

9.  Imaging of fibrogenesis in patients with idiopathic pulmonary fibrosis with cis-4-[(18)F]-Fluoro-L: -proline PET.

Authors:  Jules Lavalaye; Jan C Grutters; Ewoudt M W van de Garde; Monique M C van Buul; Jules M M van den Bosch; Albert D Windhorst; Fred J Verzijlbergen
Journal:  Mol Imaging Biol       Date:  2008-07-30       Impact factor: 3.488

10.  Lung scintigraphy with nonspecific human immunoglobulin G ((99m)Tc-HIG) in the evaluation of pulmonary involvement in connective tissue diseases: correlation with pulmonary function tests (PFTs) and high-resolution computed tomography (HRCT).

Authors:  Ch Kostopoulos; J Koutsikos; C Toubanakis; L A Moulopoulos; Ch Mamoulakis; E Gialafos; P P Sfikakis; Ch Zerva; M Mavrikakis; A Leondi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-06       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.